Business Wire

Boehringer Ingelheim and Lilly present full results from EASE Phase III programme for empagliflozin as adjunct to insulin in type 1 diabetes

Del

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today that empagliflozin met the primary efficacy endpoint, defined as a change from baseline in HbA1c versus placebo after 26 weeks of treatment, for all doses investigated (2.5, 10 and 25 mg) in the Empagliflozin as Adjunctive to inSulin thErapy (EASE) Phase III programme in adults with type 1 diabetes. The EASE programme results were published online in Diabetes Care ahead of print and presented at the 54th EASD Annual Congress in Berlin on 4th October, 2018.1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181004005237/en/

Empagliflozin is currently not approved for use in type 1 diabetes.

The EASE-2 study evaluated doses of 10 and 25 mg of empagliflozin as adjunct to insulin over 52 weeks, while the EASE-3 study evaluated doses of 2.5, 10 and 25 mg of empagliflozin as adjunct to insulin over 26 weeks. In EASE-2, placebo-corrected mean change from baseline in HbA1c at week 26 was -0.54% and -0.53% for empagliflozin 10 and 25 mg, respectively. In EASE-3 placebo-corrected mean change from baseline in HbA1c at week 26 was -0.28%, -0.45% and -0.52% for empagliflozin 2.5 and 10 and 25 mg, respectively. In addition to reduction in HbA1c, empagliflozin treatment was effective on secondary endpoints, showing reductions in weight, decreases in blood pressure, and decreases in total daily insulin dose.1

In addition, data from continuous glucose monitoring in the EASE programme indicates that patients treated with empagliflozin had improved glycaemic variability and spent more time in range, although the data for the 2.5 mg dose are limited.1

There was no increase in the risk of investigator-reported hypoglycaemic events, including severe hypoglycaemia, with empagliflozin treatment, which was a key secondary endpoint in the trials. Additionally, a reduction in patient-reported hypoglycaemic events was observed. The number of adjudicated diabetic ketoacidosis (DKA) events was comparable between empagliflozin 2.5 mg and placebo, and higher than placebo with empagliflozin 10 and 25 mg. Apart from incidence of DKA, the safety profile observed in the EASE programme was generally consistent with the previously reported safety profile of empagliflozin in adults with type 2 diabetes.1

“The goal of the EASE programme was to determine if treatment with empagliflozin could benefit people with type 1 diabetes as an adjunct to insulin,” said Bernard Zinman, M.D., Professor in the Department of Medicine, University of Toronto and Senior Scientist at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada. “Given the risk of DKA for people with type 1 diabetes, the 2.5 mg empagliflozin dose warrants consideration, as it balances glycaemic and metabolic improvements that are relevant to patients without increasing their risk of DKA or other serious adverse events.”

Based on the totality of the EASE data Boehringer Ingelheim has initiated regulatory discussions for empagliflozin as adjunct to insulin for adults with type 1 diabetes.

“The EASE programme demonstrated that empagliflozin helps patients with type 1 diabetes to remain within their target glucose range better than insulin alone,” said Dr. Jyothis George, Global Head of Clinical Development, Therapeutic Area CardioMetabolism, Boehringer Ingelheim. “There are currently no oral treatment options available for people with type 1 diabetes and these results show that empagliflozin could benefit these individuals. We look forward to working with regulatory authorities to explore whether this potential treatment can be made available to adults with type 1 diabetes.”

Jeff Emmick, M.D., Ph.D., Vice President of Product Development for Lilly Diabetes, added: “The Boehringer Ingelheim-Lilly Diabetes Alliance is committed to helping people improve the management of their diabetes, and the EASE programme is part of our broader efforts to explore treatment options that address unmet needs.”

About Diabetes

An estimated 425 million adults worldwide have type 1 and type 2 diabetes.2 Type 2 diabetes is the most common form, accounting for around 90 percent of all cases.2 Diabetes is a chronic disease that occurs when the body does not properly produce, or use, the hormone insulin.

About the EASE Phase III programme

The EASE Phase III programme includes two multinational, double-blinded, placebo-controlled Phase III clinical trials to investigate the efficacy, safety and tolerability of once-daily Empagliflozin as Adjunctive to inSulin thErapy in adults with type 1 diabetes (EASE), an indication for which empagliflozin is currently not approved.

  • EASE-2 [NCT02414958] evaluated 10 and 25 mg doses of empagliflozin as adjunct to insulin versus placebo for 52 weeks3
    Primary endpoint: Change from baseline in HbA1c after 26 weeks of treatment
    Number of patients: 720
  • EASE-3 [NCT02580591] compared 2.5, 10 and 25 mg doses of empagliflozin as adjunct to insulin versus placebo for 26 weeks4
    Primary endpoint: Change from baseline in HbA1c after 26 weeks of treatment
    Number of patients: 960

About empagliflozin

Empagliflozin is an SGLT2 inhibitor, which provides blood sugar control with additional benefits of weight loss and lowering blood pressure* in adults with type 2 diabetes. Empagliflozin is the first and only oral diabetes medicine approved to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. The benefit-risk profile of empagliflozin has been well-established in its approved indications. Type 1 diabetes is currently not an approved indication of empagliflozin.

* Jardiance ® is not indicated for weight loss or blood pressure reduction.

Please click on the following link for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/Empa-T1D-Full-Data

Contact information

Boehringer Ingelheim
Dr Petra Kienle
Product Communication Manager
Email: press@boehringer-ingelheim.com
Phone: +49 (6132) 77 143877
or
Lilly Diabetes and Lilly USA
Greg Kueterman
Director of Communications
Email: kueterman_gregory_andrew@lilly.com
Phone: +1 (317) 432-5195

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Moon-Walking Mini-Breaks, 3D-Printed Room Service and Hyper-Personalised Spaces: Welcome to the Hotel of 211919.6.2019 10:05:00 CESTPressemelding

Intergalactic getaways, fast-food nutrient pills, 2-3 hour working days and adaptable, personalised rooms that can transport guests everywhere from jungles to mountain ranges; in celebration of its 100th anniversary, today Hilton (NYSE: HLT) predicts the future trends set to dominate the travel and hospitality industry in the next 100 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005341/en/ Autonomous shooting travel pods will drop guests off at mesmerising destinations, while miniature eco-systems protected from the elements by bubble-like structures will mirror their surroundings (Photo: Business Wire) In a report supported by expert insight from the fields of sustainability, innovation, design, human relations and nutrition, findings reveal how the growing sophistication of technology and climate change will impact the hotel industry in the future. Key predictions for the hotel of the future include: Persona

Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTA19.6.2019 10:00:00 CESTPressemelding

Invivoscribe is pleased to announce that on June 5th the Ministry of Health, Labor and Welfare (MHLW) approved our LeukoStrat® CDx FLT3 Mutation Assay as the companion diagnostic for Daiichi Sankyo’s Quizartinib for the treatment of FLT3-ITD positive relapse/ refractory acute myeloid leukemia (AML) patients in Japan. At the same time the Japanese MHLW added approval in use of EDTA collection tubes to the existing approval of heparin collection tubes used with this assay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005222/en/ Invivoscribe Headquarters - San Diego, CA (Photo: Business Wire) The QuANTUM-R study demonstrated that quizartinib resulted in a statistically significant improvement in overall survival (OS) compared to salvage chemotherapy when patients were selected with the LeukoStrat CDx FLT3 Mutation Assay. Mutations in the FLT3 gene are among the most important driver mutations in AML. This milestone furt

BearingPoint Acquires Public Services Consultancy Prederi in the UK19.6.2019 08:50:00 CESTPressemelding

Management and technology consultancy BearingPoint made a strategic move by acquiring Prederi, a leading consultancy focused on public services in the UK. The acquisition supports BearingPoint’s overall growth objectives, strengthens its presence in the UK, and broadens its public service capabilities. With this transaction, two highly profitable companies join forces. Prederi provides expert advice and consultancy and serves a large number of prestigious UK public sector clients. For many years, Prederi has been generating stable revenue streams. The Prederi team now expands BearingPoint’s expertise and capabilities in one of the largest and most competitive public services markets in Europe. “With the acquisition of Prederi we are continuing our growth strategy in selected markets with consultancies that are highly focused and strongly differentiated,” said Kiumars Hamidian, Managing Partner of BearingPoint. “Prederi's portfolio is a perfect complement to our public service strategy

HCL Technologies Selected by Cricket Australia as Digital Technology Partner19.6.2019 07:52:00 CESTPressemelding

HCL Technologies (HCL) and Cricket Australia (CA) have today announced a multi-year partnership, with HCL being chosen as the Digital Technology Partner of CA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005284/en/ HCL Technologies and Cricket Australia exchanging mementos to announce digital partnership. Standing left to right: Brad Hodge, former Australian international cricketer, & current cricket coach; Arthur Fillip, Executive Vice President - Sales Transformation & Marketing; Kevin Roberts, CEO, Cricket Australia; Swapan Johri, Corporate Vice President & Head - Asia/Pacific & Middle East Business; Belinda Clarke, Executive General Manager, Community Cricket & former captain of the Australian Women's Cricket Team (Photo: Business Wire) HCL, a leading global technology company, will help the Australian cricket’s governing body provide an elevated and immersive digital experience to cricket fans, players, partner

Sartorius Starts up Operations at Expanded Site in Puerto Rico19.6.2019 07:30:00 CESTPressemelding

After investing more than 100 million U.S. dollars, Sartorius, a leading international partner of biopharmaceutical research and the industry, started up its expanded manufacturing operations in Yauco, Puerto Rico. The U.S. market is primarily supplied from this site, given that Sartorius has been growing strongly in this marketplace at above-average rates over the past several years. “Operationally and strategically, this expansion is an important investment for us. The considerably higher production capacities created as a result now give us leeway to deliver an even wider product array directly from the region to our American customers and to implement our ambitious growth plans in the Americas,” said Sartorius Executive Board Chairman and CEO Joachim Kreuzburg to approximately 500 employees and guests at the opening ceremony on Tuesday in Yauco. The company substantially extended the plant in Puerto Rico within a construction phase of around three years, more than doubling producti

comforte AG Gives Apache Kafka a Big Data Security Boost19.6.2019 07:14:00 CESTPressemelding

comforte AG, a leading provider of enterprise data security and digital payments solutions, has announced new integration capabilities for Apache Kafka with the latest release of its Enterprise Data Protection Suite. Apache Kafka is a distributed data streaming platform that allows users to collect and examine real-time data streams from a variety of popular applications. These new capabilities enable organizations to integrate data protection methods, like tokenization or format-preserving encryption, into their Kafka environments. Anonymization and pseudonymization can be applied to sensitive data on the fly within Apache Kafka to help organizations protect information and fulfil compliance regulations. The additional capabilities cater to use cases unique to the Apache Kafka environment, especially Kafka Connect and Kafka Streams. The release will be making its debut at Whitehall Media’s Big Data Analytics Conference in London, the industry event showcasing the latest Big Data Analy